FT.MDR.74: intra-articular hyaluronic acid device officially registered in Iraq
We are pleased to announce that the FT.MDR.74 medical device has been officially registered with the Ministry of Health of the Republic of Iraq, confirming full compliance with international regulatory standards and its high profile of quality and safety.
FT.MDR.74 is a Class III medical device designed as a synovial fluid substitute for the treatment of degenerative and post-traumatic joint diseases.
Thanks to its viscoelastic and lubricating properties, the device restores the physiological conditions of the joint, improving mobility and reducing pain.
Its mechanism of action is based on the use of linear hyaluronic acid with a high molecular weight (1000–1500 kDa), obtained through biotechnological synthesis, free from animal-derived components and suitable for sensitive patients or those with contraindications to biological materials.
Its main clinical actions include:
- Restoring the viscosity and elasticity of synovial fluid.
- Reducing joint pain associated with osteoarthritis and trauma.
- Protecting cartilage from degenerative processes.
- Stimulating the endogenous biosynthesis of hyaluronic acid.
FT.MDR.74 is supplied in 2 ml pre-filled syringes, with optimized dosage ensuring precise and safe intra-articular administration, minimizing the risk of contamination and dosing errors.
The registration with the Iraqi Ministry of Health strengthens the international presence of the device, making it immediately available for commercialization (ready to market) and in private label version for distributors seeking a certified solution with complete regulatory support.
This approval represents a strategic milestone for expanding into the Middle Eastern market of intra-articular medical devices — a rapidly growing sector driven by the increasing incidence of osteoarthritic conditions and the rising adoption of non-invasive viscosupplementation therapies.
The fact that the FT.MDR.74 medical device is already registered in Iraq allows to:
- Speed up commercial market entry
- Avoid lengthy documentation procedures
- Collaborate with a partner who has already completed all authorization stages
Being pre-approved in a target country represents a strong strategic and commercial advantage, especially in the medical device sector, where registration timelines can directly affect business planning and profitability.
Certified manufacturer of medical devices, dietary supplements, and dermocosmetics, offers FT.MDR.74 ready to market or available in private label version with full regulatory and technical support.
